The Case for Earlier Detection of Parkinson’s Disease
A Scientific Rationale for the Parkinson's Early Detection Framework (PEDF)
Executive Summary
Parkinson's disease (PD) is typically diagnosed by clinical evaluation of motor symptoms such as tremor, rigidity, and slowed movement. By the time clinical diagnosis occurs, however, the disease process has often been underway for many years. Research now demonstrates that Parkinson's disease can have a prolonged prodromal phase during which non-motor symptoms including REM Sleep Behavior Disorder (RBD), loss of smell, constipation, autonomic dysfunction, depression, and subtle cognitive changes appear years before a clinical diagnosis is made.¹–⁴
This evolving understanding has significant implications for patient care. While no currently approved therapy has been proven to stop or reverse Parkinson's disease, earlier recognition provides meaningful clinical benefits. Patients can receive earlier treatment for non-motor symptoms, begin evidence-based exercise and rehabilitation sooner, access specialized care earlier, participate in clinical research, and prepare for emerging disease-modifying therapies.
The Parkinson's Early Detection Framework (PEDF) is a multidisciplinary model designed to help healthcare professionals recognize individuals who may be in the prodromal phase of Parkinson's disease and guide them toward timely evaluation and appropriate care. It is not intended to diagnose Parkinson's disease independently. Rather, it provides a practical framework for identifying individuals at increased risk and coordinating the next steps in their care.
The Challenge
Parkinson's disease is viewed primarily as a movement disorder. Diagnosis depends on the presence of motor symptoms severe enough to satisfy established clinical criteria. While those criteria remain essential, they represent a relatively late stage in the disease process.³
Today, researchers recognize Parkinson's disease as a progressive, multisystem neurodegenerative disorder that often begins long before motor symptoms develop. During this prodromal phase, abnormal alpha-synuclein pathology and dysfunction in multiple neurological systems may already be present, producing symptoms that are evaluated in isolation rather than recognized as part of a developing neurodegenerative disease.²,⁴
Many individuals who later develop Parkinson's disease first seek care for sleep disturbances, constipation, urinary symptoms, dizziness, depression, anxiety, chronic pain, loss of smell, or any number of discrete complaints. Because these symptoms are common and nonspecific, they may be treated separately for years before Parkinson's is considered. This fragmented approach can lead to unnecessary testing, short-term treatments that overlook a shared neurological cause, and medications that can worsen other problems such as orthostatic hypotension, constipation, cognitive impairment or fall risk. Recognizing the broader pattern can improve both earlier detection and the safety and coordination of care.
Why Earlier Detection Matters
Earlier detection doesn’t change an underlying Parkinson’s diagnosis, but it can significantly improve the way the disease is managed.
Earlier Treatment of Non-Motor Symptoms
Many of the symptoms that have the greatest impact on quality of life occur before motor impairment becomes prominent. Sleep disorders, autonomic dysfunction, depression, anxiety, constipation, fatigue, urinary dysfunction, and chronic pain can often be evaluated and treated well before a formal diagnosis of Parkinson's disease is established. Earlier recognition allows prodromal symptoms to be managed in the context of the underlying disease, improving function and quality of life while reducing the risk of fragmented, inappropriate or counterproductive treatment.
Earlier Exercise and Rehabilitation
Exercise is widely regarded as one of the most beneficial interventions currently available for people living with Parkinson's disease. Studies consistently demonstrate improvements in mobility, balance, strength, cardiovascular fitness, and overall function. Physical therapy, occupational therapy, and speech therapy are also most effective when introduced before significant disability develops. Earlier identification allows patients to begin these interventions proactively rather than reactively.⁵
Better Care Coordination
Because Parkinson's affects multiple body systems, comprehensive care often requires collaboration among neurologists, primary care physicians, therapists, mental health professionals, and other specialists. Earlier recognition provides an opportunity to establish this multidisciplinary approach before complications become more difficult to manage.
Participation in Clinical Research
The greatest promise of early detection may lie in the future. Most investigational therapies designed to slow or modify Parkinson's disease are expected to have their greatest effect before extensive neuronal loss has occurred. Identifying individuals during the prodromal phase expands opportunities to participate in clinical trials evaluating neuroprotective therapies, biomarkers, and precision medicine approaches.
Planning and Patient Education
Earlier identification also allows patients and families more time to understand the disease, establish healthy lifestyle habits, connect with support resources, and make informed decisions regarding their future care. Knowledge alone does not change disease progression, but it enables patients to become active participants in their care from the earliest stages of disease.
The Missing Link
Scientific understanding of Parkinson's disease has advanced rapidly. Clinical practice is advancing more slowly. Patients experiencing prodromal symptoms frequently enter the healthcare system through specialties other than neurology. Sleep medicine physicians evaluate REM Sleep Behavior Disorder. Gastroenterologists treat chronic constipation. Urologists manage bladder dysfunction. Cardiologists evaluate orthostatic hypotension. Psychiatrists treat depression and anxiety. Primary care physicians often coordinate care for all of these conditions.
Each specialty addresses its own clinical concerns appropriately. What is often missing is a mechanism for recognizing when multiple seemingly unrelated symptoms may represent a developing neurodegenerative disorder. The challenge is not simply identifying individual symptoms. It is recognizing the pattern.
The Parkinson's Early Detection Framework (PEDF)
The Parkinson's Early Detection Framework was developed to address this gap.
PEDF is a multidisciplinary clinical framework designed to improve awareness of prodromal Parkinson's disease, encourage recognition of established risk factors and symptom patterns, support appropriate screening strategies, and facilitate timely referral for neurological evaluation when indicated.
The framework is intended to complement (not replace) existing diagnostic criteria established by the International Parkinson and Movement Disorder Society. It does not diagnose Parkinson's disease. Instead, it helps identify individuals who may benefit from further evaluation based on current scientific evidence.
PEDF also provides a structure that can evolve as new biomarkers, imaging techniques, wearable technologies, and disease-modifying therapies become available.
Conclusion
Parkinson's disease begins long before it is traditionally diagnosed. Increasing scientific evidence demonstrates that its earliest manifestations often appear years before the development of recognizable motor symptoms.
Earlier recognition offers meaningful benefits that are available today, including improved management of non-motor symptoms, earlier rehabilitation, better care coordination, expanded access to clinical research, and greater patient engagement. As advances in biomarkers and disease-modifying therapies continue, the importance of identifying Parkinson's disease during its earliest stages will only increase.
The Parkinson's Early Detection Framework provides a practical, evidence-informed approach for translating this evolving scientific understanding into earlier recognition and more coordinated patient care.
References
Berg D, Postuma RB, Adler CH, et al. MDS Research Criteria for Prodromal Parkinson's Disease. Movement Disorders. 2015;30(12):1600-1611.
Heinzel S, Berg D, Gasser T, et al. Update of the MDS Research Criteria for Prodromal Parkinson's Disease. Movement Disorders. 2019;34(10):1464-1470.
Postuma RB, Berg D, Stern M, et al. MDS Clinical Diagnostic Criteria for Parkinson's Disease. Movement Disorders. 2015;30(12):1591-1601.
Postuma RB, Berg D. Advances in Markers of Prodromal Parkinson Disease. Nature Reviews Neurology. 2016;12:622-634.
Bloem BR, Okun MS, Klein C. Parkinson's Disease. The Lancet. 2021;397:2284-2303.